Lead Product(s) : Vecabrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program
Details : Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies.
Brand Name : SNS-062
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2020
Lead Product(s) : Vecabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?